Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC210 crossover fMRI study in adults with generalized anxiety disorder
2014-004937-15Phase 2Unknown
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of soclenicant in generalized anxiety disorder (GAD), sponsored by Neuphoria Therapeutics Inc. Status: unknown.
02
Drugs
soclenicant
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2014-004937-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004937-15.